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A recent study showed that cAMP analogs lowered may also be present “short-loop’’feedback systems in tissues,
cAMP levels in rat hepatocytes (Corbin, J. D., Beebe, which cause a rapid dampening of cAMP levels. It has been
S . J., and Blackmore, P. F. (1985)J. Biol. Chern. 260, reported that P-adrenergic agonists rapidly increase the activ8731-8735). Thepresentworkdemonstrates
that ity of low K,,, phosphodiesterases in liver (5-6) and fat(7-lo),
cAMP analogs also lowered cAMP in a rapid, concen- but the relative importance of phosphodiesterase activation
tration-dependent manner in heart and fat cells. In in modulating cAMP levels under these circumstances has
order to determineif the CAMP-dependent protein ki- been difficult to assess since cAMP levels are determined by
nase mediated this effect, techniques were developed the composite of adenylate cyclase and phosphodiesterase
to assay the protein kinase activity
ratio inhepatocytes
treated with cAMP analogs. The activation of protein activities. Cyclic AMP analogs offer the attractionof bypasskinase and phosphorylase in hepatocytes by 8-pC14S- ing adenylate cyclase and activating the CAMP-dependent
protein kinase directly (11).Several studies have shown that
cAMP (where 8-pClI#JS-indicates8-parachlorothiocAMP analogs activate the low K , phosphodiesterase (5-6,
phenyl-) was concentration-dependent and occurred in
CAMP. More IO), thus predicting that they wouldlower cAMP levels in
paralleltoproportionatedecreasesin
intact cells, although one early experiment showed that the
than 20% of the cAMP binding sites on the protein
kinase wereunoccupied at concentrations of 8-pClgS- analog N6,02’-dibutyryl-cAMPelevated cAMP levels in adicAMP that produced maximal cAMP lowering. Thus, pocytes (12). More recent work with cAMP analogs having
the possibility that 8-pCl4S-cAMP lowered cAMP by high affinity for protein kinase and relatively low affinity for
displacing it from protein kinase binding
sites, making phosphodiesterase has shown that cAMP analogs lower enit available for hydrolysis, seemed unlikely. In adipo- dogenous cAMP in hepatocytes (13). Preliminary evidence
cytes, the lowering of cAMP by 8-pC14S-cAMP oc- suggests that CAMP-dependent protein kinase mediates this
curred inparallel with increases in lipolysis and acti- effect, but the mechanism and its physiological significance
vation of low K,,,
phosphodiesterase, suggesting that
remain unclear. The objectives of the present study were to
the phosphodiesterase was responsible for the cAMP
lowering. Further evidence for this assertion was the examine the mechanism of rapid cAMP lowering in hepatofinding that inhepatocytes preloaded with low concen- cytes and look for occurrence of this phenomenon in other
trations of 8-pCL$S-cAMP,glucagon lowered 8-pClI#JS- cell types. Using heart, liver, and fat cells, it is shown that
cAMP by about 50%, an amount similar to the cAMP CAMP-dependent protein kinase-mediated lowering of cAMP
lowering observed with 8-pClI#JS-cAMP
treatment. The may be a general mechanism for regulating cAMP levels and
results were consistent with a CAMP-dependent pro- may occur through phosphodiesterase activation. It is also
tein kinase-catalyzed activation of a phosphodiesterase suggested that this phenomenon may represent an example
and suggested that 8-pCl4S-CAMP-mediatedhydroly- of a second messenger regulating its own concentration.
sis of cAMP mimicked a physiologically significant
response. The observation of this phenomenon in sevMATERIALSANDMETHODS
eral tissues further suggested that it may be a general
Preparation and Incubation of Hepatocytes-Hepatocytes were isomechanism for dampening and terminating the horlated from male Sprague-Dawley rats (200-250 g body weight) by
monal signalthroughaccelerateddegradation
of collagenase perfusion as previously described (14). Cyclic AMP anaCAMP.
logs were added to continually gassed cell suspensions (50 mg cells/

Chronic exposure of certain tissues to hormones that elevate cAMP produces a state of “refractoriness” to further
hormonal stimulation. Dampening
mechanisms such as downregulation of hormone receptors and/or uncoupling of the
receptor-adenylate cyclase complex have been described (14) and may represent “long-loop” feedback systems. There
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Vanderbilt University, Nashville, T N 37232.

ml) incubated at 37 ‘C, and aliquots were removed for measurement
of phosphorylase, CAMP-dependent protein kinase, and CAMP. 50and 5OO-pl aliquots of each cell suspension were removed for subsequent assay of CAMP-dependent protein kinase and phosphorylase,
respectively. Cyclic AMP was assayed in cell pellets obtained by
centrifuging (500 X g) 4 mlof cell suspension and decanting the
supernatant. Bothaliquots and thecell pellet were immediately frozen
in liquid nitrogen and stored at -70 “C.
Protein Kinase Assay-The protein kinase activity ratio was determined by a modification of the filter paper assay of Roskoski (15),
using asynthetic heptapeptide (Leu-Arg-Arg-Ala-Ser-Leu-Gly)
as
substrate. Preliminary studies were undertaken to assure that the
activity ratio could be accurately measured in hepatocyte incubations
containing cAMP analogs. The use of larger than normal volumes of
homogenizingbuffer diluted the cAMP analogs and circumvented the
problem of additional activation of the enzyme after homogenization.
4 mlof homogenizing buffer containing 10 mM KH,PO,, 150 mM
and bovine
KCl, 10 mM EDTA, 0.5 mM 3-isobutyl-l-methylxanthine,
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assayed in incubations with Type I CAMP-dependentprotein kinase
partially purified through the DEAE-cellulose step (17). The activity
ratio was varied by the addition of various concentrations (31-1000
nM) of 8-pClqhS-CAMP to a total volume of 95 pl reaction mixture
containing 6 pmol of holoenzyme, 20 mM Tris-HC1 (pH 7.4), 0.05mM
3-isobutyl-l-methylxanthine,
65 pM heptapeptide (Kemptide), 10 mM
Mg(CH&00)2, 0.1 m M 13*P]ATP(-100 cpm/pmol), and 0.39 p~
[3H]cAMP in the presence and absence of 2 p~ cold CAMP. After
incubation at 4 "C, 50-pl aliquots were spotted on phosphocellulose
papers for determination of 32Pincorporation. To the45 p1 ofreaction
mixture remaining, 1 ml of cold 10 mM KH2P04containing 1 mM
EDTA was added, andthis sample was filtered immediately by
Millipore filtration as previously described (18).
Preparation and Incubation of Adipocytes-Adipocytes were isolated from epididymal fat pads of 200-250 g male Sprague-Dawley
rats by collagenase treatment according to Rodbell (19). The cells
were washed and resuspended (10 mg cells/ml suspension) in KrebsRinger bicarbonate buffer containing 1 mM CaClz and 2% BSA.
Duplicate incubations were carried out in closed vials gassed with
95% 0 2 and 5%CO2 in the presence or absence of various concentrations of 8-pCl@S-cAMP.At the end of a 15-min incubation, the cells
were washed twice with 0.25 M sucrose in 10 mM TES, and one
replicate of each incubation was immediately homogenized with 1 ml
of cold buffer containing 25 mM NHdHCO3, 1 mM 3-isobutyl-methylxanthine, and 20 mM EDTA. The homogenate was boiledfor 6 min
and centrifuged for 7 min in a Beckman Microfuge B. The aqueous
phase was recovered and chromatographed at 4 "C on Sephadex G25, and cAMP was assayed in the appropriate fractions as described
for hepatocytes. The other replicate of each incubation was retained
for assay of phosphodiesterase. Glycerol release was determined in
similar incubations according to themethod described by Beebe et al.
(20).
Assay of Low K,,, Phosphodiesterase-Crude microsomal fractions
(P-2) were prepared from each adipocyte incubation, and phosphodiesterase activity was measured according to the method described
by Kono (21). The assay procedure involved measurement of adenosine formation from tritiated cAMP hydrolysis by phosphodiesterase
and snake venom nucleotidase. The reaction was initiated by adding
50 plof the crude enzyme to 200 pl of reaction mixture containing 50
mM TES(pH 7.5),0.125 p~ unlabeled CAMP, 1 pCi [3H]cAMP
(specific activity 31 Ci/mmol), and 5 mM MgSO,. The reaction was
stopped after a 5-min incubation a t 30 'Cby adding 250 pl of an
equimolar mixture of cAMP and AMP (1mM each) and immediately
boiling for 3 min. After the tubes cooled, 50 plof 5 mg/ml snake
venom in 0.1 M Tris (pH 8) was added to each tube and incubated
for 30 min a t 37 "C. This reaction was terminated by a 50-pl addition
of 5 mM adenosine in 200 mM EDTA. Tritiated adenosine was
separated from 13H]cAMPby QAE-Sephadex and counted. Protein
in each original enzyme preparation was determined by the method
of Bradford (22), and phosphodiesterase activity was expressed as
pmol of cAMP hydrolyzed/min/mg of protein.
Preparation and Incubation of Cardiomyocytes-Cardiomyocytes
were isolated by collagenase perfusion of rat hearts as described
previously (23-24) with slight modification. Hearts wereremoved
quickly from anesthetized rats (250-300g) and perfused by the
Langendorff procedure. The initial perfusion was for 10 min at 60
mm mercury with Krebs-Henseleit bicarbonate buffer (37 "C, pH 7.4)
containing 1.25 mM Ca2+and 10 mM glucose (25). The perfusion was
continued for 5 additional min (8 ml/min) with no Ca" in thebuffer.
The final perfusate was changed to include 12.5 p~ Caz+, 0.1%
collagenase, and 0.1% BSA, and perfusion continued for 14 min (8
ml/min). The ventricles were excised and incubated for 10 min on a
shaker bath at 37 "C in 5 ml of Krebs-Henseleit bicarbonate buffer
containing 12.5 p~ Ca2+,0.1% collagenase, and 2% BSA. The initial
supernatant was discarded and 5 ml of fresh buffer added. Isolated
cells were harvested by repeated (three times) 5-min incubations in
the collagenase buffer, followed by pouring the suspended cells
through nylon mesh after each incubation. Cells were centrifuged at
low speed after two washes in Krebs-Henseleit buffer containing 12.5
p~ Ca2+and 2% BSA. The cells were subsequently incubated on a
shaker bath for 10 min at 37 "C in Krebs-Henseleit buffer containing
12.5 p~ Ca2+and 2% BSA. The cells were then allowed to settle twice
under gravity; the first time for 10 min at room temperature and the
second for 5 min at room temperature in a final Krebs buffer conThe abbreviations used are: BSA, bovine serum albumin; 8- taining 10 mM glucose, 1.8 mM Ca2+,and 0.01%BSA. Cells were
pCl$S-, 8-parachlorothiophenyl-; V,/V,, elution volume/total column resuspended in this buffer at a concentration of 180,000 cells/ml and
volume; TES, N-tris[hydroxylmethyl]methyl-2-aminoethanesulf0nic preincubated for 5 min at 37 "C before addition of 8-pCl$S-cAMP.
Following a 15-min incubation, cells were centrifuged at 500 X g for
acid.

serum albumin (BSA,' 0.5 mg/ml) were added to the cell pellet, and
the suspension washomogenized for 15 s using an Ultra-Turrax
TissuemizerO. Homogenates (25 pl) were immediately assayed for
protein kinase activity in the presence and absence of 5 p~ cAMP
(16). The reaction was terminated after20 min of incubation at 30 "C.
The reaction was linear in the presence and absence of cAMP for at
least 30 min.
PhosphorylaseAssay-Frozen aliquots of the cell suspensions were
thawed for 10 min and homogenized for 10 s in 1 ml of buffer
containing 150 mM @glycerophosphate, 30 mM EDTA, 150 mM NaF,
600 mM sucrose, and 6.5 mg/ml cysteine. Homogenates were assayed
for phosphorylase activity as previously described (14).
Purification and Assay of CAMP-Crude extracts were prepared by
homogenizing cell pellets in 1 ml of cold buffer containing 25 mM
and 20mM EDTA.
NH,HC03, 1 mM 3-isobutyl-l-methylxanthine,
The homogenate was boiled for 6 min and centrifuged for 7 min in a
Beckman Microfuge B. Tritium-labeled cAMP (-20,000 dpm) was
mixed with 0.5 ml of the extract and chilled before Sephadex G-25
(superfine) chromatography (0.9 X 14 cm) at 4 "C. 1-ml fractions
were collected, and 50-pl aliquots of the fractions were counted to
locate the cAMP peak and calculate recovery in these fractions. Cyclic
AMP was assayed in the appropriate fractions (11-15, VJV, = 1.62)
using Type 1 CAMP-dependent protein kinase purified from rabbit
muscle (17). Incubation of the assay was at 4 "C for 16 h, as previously
described (13).
Few studies have been reported in which cAMP levels have been
measured in tissues treated with cAMP analogs (12-13). It is important topurify cAMP analogs prior to use, since any cAMP contamination of the original preparation will copurify with endogenous
cAMP and inflate the estimated concentration. Other contaminating
cyclic nucleotides may also copurify and cross-react in the cAMP
assay. Preliminary studies in this lab (data not reported) with cardiomyocytes revealed that cyclic nucleotide contamination in commercial analog preparations can be substantial and interfere measurably in cAMP assays. The 8-pClqhS-CAMPused for cell incubations
was first chromatographed on a0.9 X 57-cm Sephadex G-25 superfine
column as previously described (12). The peak fractions of the elution
profile (V,/V, = 2.36-2.81) were combined and standardized on the
basis of absorbance at 281 nm.
Assay of 8-pC1qhS-CAMP-In some experiments, hepatocytes were
incubated with 0.015 p~ 8-pClqhS-CAMPin the presence and absence
of glucagon (5 X lo-' M), and
8-pClqhS-CAMP was
assayed. Incubation
of hepatocytes with this concentration of8-pC1&3-cAMP did not
detectably activate protein kinase or phosphorylase. Crude extracts
were prepared and chromatographed as described for purification of
CAMP,except that fractions containing 8-pClqS-cAMP were retained
for assay. Sephadex G-25 chromatography at 4 "C separated cAMP
(VJV, = 1.62) from 8-pClqhS-CAMP(VJV, = 2.78) completely (13).
Since labeled 8-pCl@S-cAMP was unavailable, all fractions (20-30)
expected to contain 8-pClqScAMP ( Ve/Vt= 2.36-2.81) were pooled.
The pooled fractions from each incubation were lyophilized and
resuspended in 25 mM NH4HC03. 60-pl aliquots were assayed using
Type 1 CAMP-dependentprotein kinase as described for the assay of
CAMP. Purified 8-pClqhS-CAMPdissolved in the elution buffer was
used as the standard. The K,, of Type 1 CAMP-dependent protein
kinase for 8-pC14S-cAMPwas about half that for CAMP.
Assay of CAMP Binding Sites-In some experiments, the protein
kinase activity ratio and thenumber of free and totalcAMP binding
sites on protein kinase were assayed in the same hepatocyte incubation. Free cAMP binding sites on the regulatory subunit were estimated by taking advantage of the difference between the rates of
cAMP binding and dissociation (fast binding, slow dissociation). The
procedure was initiated by adding 100 p1 of sample to 50 p1 of reaction
mixture containing 50 mM KH2P04 (pH 6.8), 1 mM EDTA, 0.5 mg/
ml Type 11-A histone mixture (Sigma), 2 M NaC1, 0.1 mM adenosine,
and 1.8 p~ [3H]cAMP. After 5 min a t 0 "C, 1 mlof cold 10 mM
KH2P04 (pH
6.8) containing 1mM EDTA was added, and themixture
filtered and washed using Millipore filters (18). The total[3H]cAMP
binding sites were measured using the same procedure except that
incubation was at 30 "C for 45 min. Exchange of prebound cAMP
was complete under these conditions (18). The proportion of free
sites was expressed as the ratio of cAMP bound at 0 and 30 "C.
In other experiments, free and total cAMP binding sites were

335

Short-term Feedback Regulation of CAMP
5 min at 0 “C. Incubation medium was decanted, and the cell pellet
was immediately frozen in liquid nitrogen
and stored at -70 “C.Cyclic
AMP was assayed in cell extracts after purification as described for
hepatocytes. Phosphorylase activitywas measured in the cell pellets
as previously described (14).
Methods of Analysis and Response Variable Characterizations-

Responsevariablesfromexperiments
in the presentstudy were
characterized using relationship functions appropriate to the shape
of the responsesurface.Responsessuch
as the CAMP-dependent
protein kinase activityratio and phosphorylase activationin relation
to concentration of 8-pCl@S-cAMP
were adequately characterizedby
the exponential given as
y = (Y

- p(2)-”@

(1)

where y = response variable (protein kinase or phosphorylase activity), x = concentration of 8-pClqS-cAMP( p M ) , a = asymptotic value
of y at infinite x , = CY - y at x = 0, and p = x at ( a / 2 )+ y intercept.
The CAMP-lowering response inrelation to increasingconcentrations
of 8-pC16S-cAMP or in relation to time was characterized by
y =6

+ x(2)-”/’

(2)

where y = response variable(CAMPconcentration),x = concentration
of 8-pClqScAMP or time, 6 = concentration of cAMP at infinite x ,
X = y intercept - 6, and T = x at (1/2 y intercept) + 6.
Parameter estimates, alongwith an estimate of their standard
errors, were obtained forEquations 1and 2 using an iterative nonlinear least squares routine in SAS (Statistical Analysis System, Cary,
NC). The parameter p, in the case of CAMP-dependent protein kinase
activity ratio or phosphorylase activation, is analogous to the more
familiar K, in the sense that it represents the value of x (8-pC16ScAMP concentration)producing a half-maximal response.In the case
of the CAMP-lowering response, the parameter 7 also represents the
value of x (S-pClqS-cAMPconcentration or time) where the halfmaximal response is seen. The parameter estimates for p and 7 thus
provide a convenient basis for comparing the concentration or time
dependence of the various responses withinand across tissues.
The results from experimentswhere 8-pC1&3-cAMP was measured
in hepatocytes treated with various CAMP-dependentprotein kinase
activators were analyzed by a one-way analysisof variance (26). The
criterion employed for assessing treatment differences was based on
a level of protection against TypeI errors of 1%(a= 0.01).
RESULTS

PROTEIN KINASE ACTIVITY

RATIO
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FIG. 1. The relationship between protein kinase activity
ratio and phosphorylaseactivity in hepatocytes treated with
or glucagon(0).The original observationsare
8-pCl$S-cAMP (0)
the mean of four replicates within eachof four experiments, and the
fitted curves were obtained by least squares. Hepatocyteswere incubated with variousconcentrations of 8-pC16S-cAMP or glucagon for
5 min. Aliquots were retained and assayed for protein kinase activity
ratio and phosphorylase activity as described under “Materials and
Methods.” G-I-P, glucose 1-phosphate.
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FIG. 2. Effect of 8-pClqjS-CAMP concentration on protein
ProteinKinase Activity Ratio Validation-Replicate
aliactivity ratio (O),phosphorylase activity (A), and enquots of hepatocytes were incubated with various concentra- kinase
dogenous cAMP (0)
in hepatocytes. The original observationsare
tions of 8-pCl@S-cAMP,and the cells were homogenized in the mean of duplicate determinationswithin eachof five experiments,
different volumes (1, 2, 4, 10, and 50 ml) of buffer. Protein and the fitted curves were obtained by least squares. Hepatocytes
kinase activity ratioswere assayed with the intent
of choosing were incubated for 5 minwith the indicated concentrations of 8a homogenization volume whichprevented subsequent protein pCl6S-CAMP. Extracts were prepared and processedasdescribed
under “Materials and Methods.” G-I-P, glucose 1-phosphate.
kinase activation by analog carryover when the cells were
broken. At higher 8-pCl$S-cAMP concentrations (>0.1 p ~ ) ,
phorylase activation (p) from the fitted glucagon (CY= 12.71
the assayed CAMP-dependent protein kinase activity ratios
f 0.30, p = 0.242 f 0.025) and 8-pCldS-cAMP (a! = 12.98 &
differed among homogenization volumes (data not shown).
This would be expectedif extracellular 8-pClqS-cAMP in the 1.01, g = 0.311 f 0.083) curves. No evidence was seen to
suggest that the response curves
were different.
original incubation was not sufficiently diluted in homogthe
It should be noted that this technique of using large hoenization volume.A homogenization volume of 4 ml was
chosen since the activity ratios using 4, 10, and 50 ml were mogenization volumes is ineffective in most cell types, since
of analog (500-2000 times
consistent regardless of 8-pC14S-cAMP concentration, a re- muchgreaterconcentrations
1or 2 ml (data not shown). Further
evidence greater) are required to produce cellular
responses. Thus, the
sult not seen with
that 4 ml of homogenization buffer provided the conditions carryover of analog when the cells are broken artifactually
for accurate in situ activity ratio estimates was obtained by elevates the CAMP-dependent protein kinase activity ratios.
examining the relationship between phosphorylase activation Effect of CAMPAnalogs on Hepatocyte CAMP-The cAMP
and CAMP-dependent protein kinase activity ratio in hepaanalog, 8-pCl@S-cAMP, activated hepatocyte protein kinase,
tocytes incubated with several concentrations
of glucagon and phosphorylase,and lowered cAMPin a concentration-dependentmanner.Theconcentrationsrequiredto
produce
8-pClqS-cAMP. The original observations and fitted curves
are presented inFig. 1. Assuming that glucagon acts entirely changes in each response were similar among all responses
by cAMPelevation, a given increment of proteinkinase
(Fig. 2). The concentrations of 8-pC14S-cAMP required to
activation by glucagon or 8-pClqS-cAMP should produce the produce half-maximal protein kinase activation (g = 0.071 &
same increment of phosphorylase activation. A formal test of 0.010 pM), half-maximal phosphorylase activation ( p = 0.031
the similarity between response curves
was provided by com- & 0.006 pM), and half-maximal cAMP lowering (7 = 0.036 f
was the
paring maximal phosphorylase activation(CY)and the CAMP- 0.006 gM) were similaramongthemeasures,as
dependent protein kinase activity ratio
a t half-maximal phos- concentration of 8-pC1dS-CAMP(0.125 pM),producing nearly
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maximal responses of all measures.
Hepatocyte CAMPBinding Studies-CAMP analogs, including 8-pCl$S-cAMP, are known to bind to the R-subunit of
CAMP-dependent protein kinase with high affinity (27-28).
It was important to rule out the possibility that 8-pCldScAMP was lowering endogenous cAMP by displacing bound
cAMP from CAMP-dependent protein kinase, thus making it
available for hydrolysis by phosphodiesterase. It can be seen
in Fig. 2 that CAMP-dependent protein kinase activation
occurred in parallel to the decline in CAMP, so evidence of
free binding sites at concentrations of 8-pCl#S-cAMP that
maximally lowered cAMP would argue against a competitive
mechanism for the lowering. Reference to Fig. 3 indicates
that as the activity ratio increased from 0.2 to 0.7 (maximal
activation = I), the percentage of free cAMP binding sites
decreased proportionately. Concentrations of 8-pCldS-cAMP
that produced an activity ratio of 0.7 also lowered cAMP
maximally. These results suggested that cAMP binding sites
were not saturatedat this concentrationof analog, and infact
free cAMP binding sites were detected. Similar studies in a
cell-free system using physiological concentrations of partially
purified CAMP-dependent protein kinase indicated the presence of free cAMP binding sites at activity ratios of 0.90 or
lower (Fig.4). Using both intactcells and thepartially purified
enzyme, free cAMP binding sites declined with increased
concentrations of 8-pCl@S-cAMP,but maximal cAMP lowering occurred at activity ratios where excess cAMP binding
sites were still available.
Assay of S-pCl$S-cAMP in Hepatocytes-Incubation of hepatocytes with 0.015 /IM 8-pCl@S-cAMPresulted in no detectable activation of CAMP-dependent protein kinase, but
the analog could readily be assayed in extracts of the hepatocytes. Addition of glucagon ( 5 nM), forskolin (20 p M ) , or
N6,02’-dibutyryl-cAMP (20 p ~ resulted
)
in lowering of 8pCl$S-CAMP in hepatocytes preloaded with the analog (Table
I). The N6,02’-dibutyryl-cAMPlowered 8-pCldS-cAMP significantly but was less effective than glucagon or forskolin.
Glucagon produced the most substantial lowering of 8-pCldScAMP (-50%), and thepercentage decrease was quite similar
to the percentage decrease in endogenous cAMP seen when
optimal concentrations of 8-pC14S-cAMP (0.25 pM) were used
to activate CAMP-dependent protein kinase. Addition of glucagon or forskolin to hepatocytes at the indicated concentra,”--

g
t-

‘0

0.2

0.4

0.6

0.8

FIG. 4. The relationship between protein kinase activity
ratio and free cAMP binding sites on Type 1 CAMP-dependent
protein kinase incubated with various concentrations of 8pC1bS-CAMP. The original observations are the mean of duplicate
determinations within each of three experiments. The enzyme was
partially purifiedfromrabbit skeletal muscle through the DEAEcellulose step (33), and 2.8 pmol of the holoenzyme was used for each
binding determination.
TABLE
I
Assay of 8-pCLpS-cAMP in hepatocytes preloaded with the analog
and treated with various agents to activate CAMP-dependent protein
kime
Treatment

8-pCl&CAMP”

0

0.025

0.075
0.05 0.10

0.1250

8pCI+S-cAMP (pM)

FIG. 3. The relationship between cAMP binding site occupancy (0)and protein kinase activity ratio (0)in hepatocytes
treated with various concentrations of 8-pC1bS-CAMP.The
original observations are the mean of duplicate determinations within
each of three experiments. Hepatocytes were incubated for 5 min
with various concentrations of 8-pCI4S-cAMP. Cells were homogenized, and free and total cAMP binding sites were determined as
described under“Materials and Methods.”

Protein kinase
activitv ratio

pmol/g tissue

36.47
0.24
18.36
0.81
0.80
21.40
-b
30.20
S.E.’
0.63
0.04
’Hepatocytes werepreincubated with 0.015 p~ 8-pCl4S-cAMP
for 5 min and treated in the indicated manner for 5 additional min.
Aliquots wereremovedfor determination of the CAMP-dependent
protein kinase activity ratio, and the concentration of 8-pC14S-cAMP
in the cell pellet was determined. The means and their corresponding
standard errors wereestimated from four experiments.
Accurate estimates of the CAMP-dependentprotein kinase activity ratio were not obtained in this incubation.
e Standard error of the mean from analysis of variance.
Control
5 nM glucagon
20 NM forskolin
20 pM dibutyUl-cAMP

tions resulted in nearly maximal CAMP-dependent protein
kinase activation (Table I).
It was presumed that 20 p~ N6,02‘-dibutyryl-cAMP also
activated protein kinase substantially. Accurate estimates of
CAMP-dependent protein kinase activity could not be obtained with 20 p~ N6,02’-dibutyryl-cAMP due to analog
carryover, but previous studies have shown that this concentration of the analog activated phosphorylase.’
Effect of cAMP Analogs on Adipocytes-Glycerol release,
low K,,, phosphodiesterase activation, and cAMP lowering
occurred in response to increasing concentrations of 8-pCldScAMP in adipocytes (Fig. 5). The concentration of analog
required to produce half-maximal glycerol release (171 k 14
p ~ and
) phosphodiesterase activation (140 f 11 p ~ were
)
similar, but were somewhat higher than the concentration
(106 f 9 p ~ required
)
for half-maximal cAMP lowering.
Higher concentrations of 8-pCldS-CAMP were required to
elicit all responses in fat cells than in hepatocytes. This
findingwas consistent with previous studies using cAMP
analogs in different tissues (11) and may be dueto differences
in cell permeability. Nevertheless, the percentage decrease in
endogenous cAMP produced by optimal 8-pCldS-cAMP concentrations (-60%) was similar to the cAMP decrease seen
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FIG.5. Effect of 8-pC14S-cAMP concentration on glycerol
phosphodiesterase (PDE) activation (O),
release (0),low K,,,
and endogenous cAMP (0)in adipocytes. The original observations are the mean of duplicate determinations within each of five
experiments.Adipocytes were incubated for 15 min withthe indicated
concentrations of 8-pCl+S-cAMP.Extracts were prepared and processed as described under “Materials and Methods.” Estimates of the
concentration of analog required to produce half-maximal glycerol

release and phosphodiesterase activation were obtained from fitted
logistic ogives as described previously (51).
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FIG.7. The relationship between phosphorylase activity (0)
and endogenous cAMP (0)
in cardiomyocytes treated with
various concentrations of 8-pC14S-cAMP. The original observations are the mean of four replicates within each of four experiments, and the fitted curves wereobtained by least squares. The

cardiomyocytes were incubated for 15 min with various concentrations of 8-pClbS-cAMP. Extracts were prepared and processed as
describedunder“MaterialsandMethods.”
G-I-P, glucose l-phosphate.
tios, sincecarryover of the analogwhen the cells were broken
produced additional enzyme activation. Basal cAMPwas lowered in the same 8-pC16S-cAMP concentration range that
activated phosphorylase, buttheconcentration
producing
half-maximal lowering of CAMP ( T = 13.99 f 5.46 p M ) was
less. Even so, reference to Fig. 7 illustrates the good correlation between phosphorylase activation and cAMP lowering.
The percentage decline (-60%) in basal cAMP in cardiomyocytes treated with 70 KM 8-pC16S-cAMP was similar to the
cAMP decline seen inadipocytes (-60%) and hepatocytes
(-50%) and the 8-pClqScAMPdecline (-50%) seen in glucagon-treated hepatocytes.
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DISCUSSION

Previous studies have shown that interactions among various hormones modify cellular cAMP concentrations insome
cell types. Some hormones are thought to exert their effects
by decreasing cAMP levels. The ability of insulin todecrease
cellular cAMP levels in glucagon-stimulated hepatocytes (29“Materials and Methods.”
33) andepinephrine-stimulated adipocytes (34-35) is well
documented. BuxtonandBrunton
(36)havedescribed
in
in hepatocytes (-50%). Incubation of adipocytes with200 pM
cardiomyocytes a decreased P-agonist-induced
cAMP accu8-pCl4S-CAMP produced
a rapid 49% decline (7= 2.23 +. 0.67 mulation by an a,-agonist-mediated activationof phosphodimin, half-time for maximal
lowering) in CAMP, whereas basalesterase. Dumont et al. (37) have shown that norepinephrine
cAMP in control cells decreased slightly during the 30-min (a2)decreases thyroid-stimulating hormone-stimulated adeincubation (Fig. 6). A previousreportdemonstratedrapid
nylate cyclase activity in thyroid slices, and cy2 agents are
cAMP lowering in hepatocytes (13) and reanalysis of those known to causedecreases in cAMP inseveral other tissuesby
(half-time for maximal cAMP acting through the Ni (inhibitory guanyl nucleotide-binding
data produced an estimate 7for
lowering) of 0.55 & 0.16 min. Inasmuch as the process ap- regulatory protein of adenylate cyclase) pathway (38). It has
peared t o be somewhat slower in fat cells than hepatocytes, also been reported that increasedcytosolic calcium activates
the hypothesis that the half-times were different in the two a calmodulin-sensitive phosphodiesterase insome tissues (39).
tissues was rejected.
These heterologous types of cAMP control may be important
Effect of cAMP Analogs on Cardiomyocytes-The concen- in modifying cellular responses to hormones. This laboratory
tration of 8-pC19S-cAMP required to activate phosphorylase has recentlydescribed a homologous type of cAMP control in
in cardiomyocytes (Fig. 7) was somewhat less than the con- which CAMP-dependent protein kinase activation lowers hecentration required to
lower cAMP inadipocytes, but was still patocyte CAMP. Additional evidence that cAMP may act to
substantially higher than in hepatocytes. Incubation of car- regulate its own concentration can be found in reportswhich
diomyocytes with 70 p~ 8-pC14S-cAMPachieved approxi- have shown that hormones which elevate cAMP activate a
mately 80% maximal activation of phosphorylase; a concen- hormone-sensitive phosphodiesterase inseveral cell types (5tration of 37.2 -C 4.2 p~ ( p ) produced half-maximal activation. 8,10,40), and it has been reported that
a low K,,, phosphodiUnder the conditions used, it was not possible to determine esterase can be phosphorylatedby protein kinase (41). Other
accurately the CAMP-dependent protein kinase activity raexamples of homologous regulation of second messenger con-

FIG.6. Time course of cAMP in control adipocytes (0)and
~
(0)The
. origiadipocytes treated with 200 p t 8-pC14S-cAMP
nal observations are the mean of duplicate determinations within
each of four experiments, and the fitted lines were obtained by least
squares. Extracts were prepared and processed as described under
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centrations canbe found in reportswhich showthat elevation
of cytoplasmic Ca2' results in activation of mechanisms which
quickly lower cytoplasmic Ca2+ (42), and elevation of cytoplasmic diacylglycerol has also been reported to cause a subsequent decline in cytoplasmic levels of this second messenger
(43).
The present results support the suggestion by this laboratory that CAMP-dependent protein kinase mediates the lowering of CAMP. Likely targets for CAMP-dependent protein
kinase would be the adenylate cyclase complex or low K ,
phosphodiesterases, the former decreasing cellular cAMP by
slowing synthesis and the latter by enhancing cAMP degradation. The present observation that glucagon enhances 8pC1dS-CAMP breakdown in hepatocytes suggests that a cellular phosphodiesterase(s) is being activated by protein kinase. The finding that 8-pCldS-cAMP activated a low K,,,
phosphodiesterase in the same concentration range that produced cAMP lowering in adipocytes further suggests that
cAMP is being lowered by phosphodiesterase activation. This
does not rule out thepossibility that cAMP analogs may have
an additional effect to lower cAMP by modifying adenylate
cyclase activity, but it should be pointed out that glucagonmediated lowering of 8-pC14S-cAMPwas nearly the same, on
a percentage basis, as analog-mediated cAMP lowering. It will
be of interest to confirm that phosphodiesterases are responsible for cAMP lowering under these circumstancesand identify which form of phosphodiesterase is the target enzyme.
The finding that thelowering of cAMP in adipocytes is wellcorrelated with activation of the low K , form of phosphodiesterase is strongly suggestive that this enzyme is the one
acted on by protein kinase. Another possibility considered is
that cytoplasmic 8-pC1dS-CAMP displaces cAMP from its
binding sites on CAMP-dependent protein kinase, thus stimulating phosphodiesterase activity by increasing substrate
availability. The resultsobtainedinbindingstudieswith
intact hepatocytes and with partially purified holoenzyme
argue against such a mechanism. Free binding sites are detected in both systems with 8-pCl@S-cAMPconcentrations
and CAMP-dependent protein kinase activity ratios
which
produced maximal cAMP lowering. These findings suggest
that additional 8-pCldS-cAMP would have to fill remaining
binding sites before significant cAMP displacement would
occur. Although in the basal state the proportion of total
endogenous cAMP bound to CAMP-dependent protein kinase
compared to unbound cAMP is large, previous studies have
shown that addition of low concentrations of cAMP analogs
to the holoenzyme actually stimulates cAMP binding (44).
The results presented here argue in favor of a CAMP-dependent protein kinase-mediated mechanism rather than an artifactual lowering through competition and displacement from
binding sites.
This laboratory has recently suggested that lowering of
hepatocyte cAMP by protein kinase activation may be a form
of negative feedback. The earlier findings and the results
presented here provide evidence that CAMP-dependent protein kinase regulates cellular cAMP levels and may represent
a short-loop feedback system for CAMP. Although it seems
plausible that this feedback system serves to dampen cAMP
levels, other functions are possible. Recent studieshave shown
that @-agonistsincrease the fractional turnoverrate for cAMP
(45), and it has been suggested that cAMP turnover may be
a central component in stimulus-response coupling (46). Obviously, the coupled stimulation of adenylate cyclase and
phosphodiesterase activities would increase the turnover rate
of CAMP.Long-loop feedback systems involving mechanisms
which produce desensitization and/or down-regulation of hor-

mone receptors have also been described (1-4). The action of
these systems results in
diminished cAMP accumulation after
chronic exposure to hormones, and refractoriness to further
hormonal stimulation. It has been assumed generally that the
long-loop feedback systems act through the receptor-adenylate cyclase, although a role for phosphodiesterase has not
been ruled out. Recent work has demonstrated a2-fold induction of the low K , phosphodiesterase in cultured cells constantly exposed to isoproterenol or cAMP analogs (47). Perhaps part of the refractoriness of these cells to hormonal
stimulation can be explained by CAMP-dependent protein
kinase-mediated activation of the additional phosphodiesterase that is present. It seems likely that the interaction of
these various mechanisms is important in determining the
hormone sensitivity of particular cells at any given time.
Previous studies have demonstrated the existence oflow
K , phosphodiesterases in cardiac tissue (48-50), but to our
knowledge it has not been shown that these forms of the
enzyme are activated by either insulin or hormones which
elevate CAMP. Comparable forms of the enzyme from liver
(5-6) and adipose tissue (7-8,lO) are hormone-sensitive. The
observation that cAMP analogs lower endogenous cAMP in
cardiomyocytes suggests the presence of a low K, hormonesensitive phosphodiesterase in thistissue, and thistechnique
may provide a convenient method for detecting the CAMPactivated enzyme in other tissues.
All tissues examined (hepatocytes, cardiomyocytes, and
adipocytes) to date have shown an 8-pC14S-cAMP-induced
lowering of CAMP,which is analog concentration-dependent.
The analog-induced cAMP lowering in the examined cell
types is a consistentresponse in the sense that theproportion
of CAMPdecline is similar among all cell types. These findings
suggest that the 8-pCldS-CAMP induced lowering of cAMP
mimicks a physiologically significant response and maybe
mediated by a common mechanism. The occurrence of this
phenomenon in several tissues further implies that it may be
a general mechanism for dampening and terminating hormonal signals.
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